$AMRS news,,,, Amyris Achieves Key Milestone in Major

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
$AMRS news,,,,

Amyris Achieves Key Milestone in Major Drug Discovery Collaboration
29 minutes ago - DJNF
Amyris Achieves Key Milestone in Major Drug Discovery Collaboration

Industry Leading uPharm Technology Platform Delivers Initial Development Work in Just Four Months for New Oncology Drug Development

EMERYVILLE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce that just months after initiating a collaboration with one of the world's leading pharmaceutical companies, it has successfully achieved the first milestone under the agreement. This milestone resulted in the creation of a robust, sensitive activity assay for an oncology target in a live yeast strain. This high-throughput assay enables screening for chemical diversity found in nature using Amyris's proprietary uPharm(TM) platform, with the potential to provide previously inaccessible molecule targets.

The uPharm platform combines two powerful technologies that can significantly accelerate and reduce the cost of new drug discovery. The Amyris platform is groundbreaking in its ability to design and scale molecules that are becoming disruptive workhorses across several industries. This capability is unique and allows broad access to a significant variety of naturally-evolved molecules in a rapid, high-throughput format. Active molecules can be scaled for production in yeast, further tested, and developed into market-ready pharmaceuticals at a cost and speed that the company believes has not been realized before in the pharmaceutical industry.

"We're excited by how quickly we've achieved initial success in this project for one of the largest and most innovative companies in the sector," said John Melo, Amyris President & CEO. "We believe our technology platform is well suited to efficiently drive advancements in drug discovery while meeting our partners' unique requirements and helping to save lives. Our demonstrated capabilities have led to signing several partnership agreements with leading global pharmaceutical companies this year. We are achieving in months what these companies have been chasing for years."

Continued Melo, "Along with more than doubling our revenue this year we are accelerating time to market for our biopharma partners. Our work to replace mammalian cells, deliver better antibiotics and discover new oncology treatments has the potential to transform drug discovery and make more available leading treatments to improve the lives of patients throughout the world."

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise(R) products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events such as the Amyris uPharm platform technology enabling development of pharmaceuticals at a cost and speed sufficient to efficiently drive advancements in drug discovery, continued achievement of, and pace of achievement for collaboration milestones, and annual revenue expectations that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including the company's liquidity and ability to fund operating and capital expenses, Amyris's reliance on third parties to achieve its goals, timing and execution risks associated with development and manufacturing, potential delays or failures in development, production and commercialization of products, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on November 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and uPharm are registered trademarks of Amyris, Inc.

Contact:

Peter DeNardo

Director, Investor Relations and Corporate Communications

Amyris, Inc.

+1 (510) 740-7481

investor@amyris.com

pr@amyris.com

(MORE TO FOLLOW) Dow Jones Newswires

November 16, 2016 08:30 ET (13:30 GMT)
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

XTransfer Partners with Shanghai Pudong Development Bank for Growth

Updated Category News Views 381

Collaboration on Cross-Border Financial Services XTransfer, recognized as a leading global B2B cross-border trade payment platform, is excited to announce its strategic partnership with Shanghai Pudong Development Bank Co. Ltd., Hong Kong Branch. This collaboration aims to enhance cross-border financial services tailored for SMEs engaged in international trade. Focus on...

Continue Reading
SmartOrderLink: Transforming B2B Order Transactions

Updated Category News Views 29

SmartOrderLink's Role in Streamlining B2B Transactions With every new business platform, there's the promise of smoother operations and less headache, and it seems like transcosmos and Kyoei Sangyo's SmartOrderLink might just cut through the chaos of B2B order transactions. Launched in Tokyo, this online order receipt platform promises to smarten up the process,...

Continue Reading
United Bancshares Sees Strong Start with Q1 2025 Results

Updated Category News Views 121

Financial Performance Overview United Bancshares, Inc. (OTCQX: UBOH) has announced significant financial achievements in early 2025, including a quarterly cash dividend declaration that reflects a solid growth trajectory. Quarterly Dividend and Earnings Highlights The Board has declared a cash dividend of $0.23 per share, marking a notable increase of 4.5%. This dividend,...

Continue Reading
Transforming Contact Center Operations: The Pulse Solution

Updated Category News Views 174

Unlock Business Potential with Pulse by OutboundIQ In the competitive matrix of today’s business landscape, effective decision-making is crucial for sustained growth. OutboundIQ has just become a pivotal player in enabling organizations to harness their data more effectively with the launch of Pulse. This innovative tool is designed specifically for contact centers,...

Continue Reading
Growth of Electronic Materials and Chemicals Market Insights

Updated Category News Views 144

Examining the Rapid Growth of the Electronic Materials and Chemicals Market The Electronic Materials and Chemicals Market is projected to reach an impressive USD 110.2 billion, fueled by consistent growth and a forecasted compound annual growth rate (CAGR) of 6.2% from 2024 to 2032. This increase is largely driven by significant advancements in electronic component...

Continue Reading